Actelion

September 24, 2015November 5, 2015

Clinical Trial Data On PH Therapy Selexipag (Uptravi) & Macitentan (Opsumit) To Be Presented At European Respiratory Society Congress

Actelion BioPharmaceuticals recently announced that the company will be releasing important data from its Phase III GRIPHON study testing the efficacy and tolerability of their pipeline drug selexipag (Uptravi®) for the treatment ... Read more

August 27, 2015November 5, 2015

Actelion to Present Data on Selexipag (Uptravi) and Macitentan (Opsumit) for PAH at Upcoming European Conference

News, Pulmonary Hypertension

Actelion Ltd, a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs, recently announced that the results of its ... Read more

May 15, 2015November 5, 2015

Actelion’s Encouraging Clinical Trial Results on PAH Therapies to be Presented at Upcoming Scientific Meeting

News, Pulmonary Hypertension

Actelion Pharmaceuticals Ltd recently announced in a press release that data from its Phase III trials on the drugs selexipag (Uptravi) and macitentan (Opsumit) will be presented at the upcoming ... Read more

March 31, 2015November 5, 2015

Opsumit Granted Marketing Approval in Japan for PAH

News, Pulmonary Hypertension

The Japanese Ministry of Health Labor and Welfare has granted marketing approval for a novel therapy developed by Actelion for pulmonary arterial hypertension (PAH). Opsumit (macitentan) was approved based on the latest data ... Read more

March 23, 2015November 5, 2015

Long-term Data on Selexipag for PAH Presented at American College of Cardiology (ACC) 2015

News, Pulmonary Hypertension

Actelion Ltd recently presented long-term results at the American College of Cardiology (ACC) Congress in San Diego, US from their pivotal selexipag (Uptravi®) Phase III GRIPHON trial. The company reported that, ... Read more

March 9, 2015November 5, 2015

Results of SERAPHIN Trial Show Macitentan PAH Treatment Decreases Hospitalization Risk

News, Pulmonary Hypertension

A group of international pulmonary medical specialists have conducted a clinical trial to assess improvement in hospital based outcomes in patients with pulmonary arterial hypertension (PAH) when treated with macitentan, ... Read more

December 30, 2014November 5, 2015

Actelion Submits New Drug for Pulmonary Arterial Hypertension to FDA

News, Pulmonary Hypertension

Actelion has submitted its new treatment for pulmonary arterial hypertension (PAH) to the U.S. Food and Drug Administration (FDA). The company is applying for a New Drug Application (NDA) for selexipag (Uptravi), after having ... Read more

December 4, 2014November 5, 2015

Experimental Pulmonary Arterial Hypertension Drug Selexipag Submitted To European Medicines Agency

News, Pulmonary Hypertension

Actelion Ltd, a biopharmaceutical company developing innovative therapeutics for orphan diseases, submitted a Marketing Authorization Application (MAA) for their lead investigational drug selexipag (Uptravi®) to the European Medicines Agency (EMA) as a new therapeutic for ... Read more